Literature DB >> 27573024

The Unexpected Roles of Aurora A Kinase in Gliobastoma Recurrences.

Estelle Willems1, Arnaud Lombard1,2, Matthias Dedobbeleer1, Nicolas Goffart3,4, Bernard Rogister5,6.   

Abstract

The main obstacle for the cure of glioblastoma (GBM) is systematic tumor recurrence after treatment. More than 90 % of GBM tumors are indeed recurrent within 5 years after diagnosis and treatment. We urgently need new therapies to specifically address these deadly relapses. A major advance in the understanding of GBM recurrence is the identification of GBM-Initiating Cells (GIC), characterized by their abilities for self-renewal, multilineage differentiation, and proliferation. It appears that these features of GIC could be modulated by the mitotic kinase Aurora A (AurA). Indeed, besides its role in mitosis, AurA has recently been identified to regulate alternative functions like cell polarity, asymmetric cell division, and epithelial to mesenchymal transition. All these properties may help explain GBM therapeutic resistance and recurrence. In this review, we make the hypothesis that AurA could significantly contribute to GBM recurrences and we focus on the possible roles of AurA in GIC.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27573024     DOI: 10.1007/s11523-016-0457-2

Source DB:  PubMed          Journal:  Target Oncol        ISSN: 1776-2596            Impact factor:   4.493


  113 in total

Review 1.  Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?

Authors:  Héctor Peinado; David Olmeda; Amparo Cano
Journal:  Nat Rev Cancer       Date:  2007-05-17       Impact factor: 60.716

Review 2.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

3.  ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action.

Authors:  Graham C Fletcher; Richard D Brokx; Trisha A Denny; Todd A Hembrough; Stacy M Plum; William E Fogler; Carolyn F Sidor; Mark R Bray
Journal:  Mol Cancer Ther       Date:  2010-12-21       Impact factor: 6.261

4.  Identification of an Aurora-A/PinsLINKER/Dlg spindle orientation pathway using induced cell polarity in S2 cells.

Authors:  Christopher A Johnston; Keiko Hirono; Kenneth E Prehoda; Chris Q Doe
Journal:  Cell       Date:  2009-09-18       Impact factor: 41.582

5.  Comparative immunohistochemical analysis of aurora-A and aurora-B expression in human glioblastomas. Associations with proliferative activity and clinicopathological features.

Authors:  Vassilis Samaras; Angeliki Stamatelli; Efstathios Samaras; Christos Arnaoutoglou; Marianthi Arnaoutoglou; Ioanna Stergiou; Paraskevi Konstantopoulou; Vassilis Varsos; Andreas Karameris; Calypso Barbatis
Journal:  Pathol Res Pract       Date:  2009-07-18       Impact factor: 3.250

6.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

7.  Radiotherapy followed by aurora kinase inhibition targets tumor-propagating cells in human glioblastoma.

Authors:  Nan Li; Dustin J Maly; Yvan H Chanthery; Daniel W Sirkis; Jean L Nakamura; Mitchel S Berger; C David James; Kevan M Shokat; William A Weiss; Anders I Persson
Journal:  Mol Cancer Ther       Date:  2014-12-18       Impact factor: 6.261

8.  Combined VEGF and CXCR4 antagonism targets the GBM stem cell population and synergistically improves survival in an intracranial mouse model of glioblastoma.

Authors:  Amy Barone; Rajarshi Sengupta; Nicole M Warrington; Erin Smith; Patrick Y Wen; Rolf A Brekken; Barbara Romagnoli; Garry Douglas; Eric Chevalier; Michael P Bauer; Klaus Dembowsky; David Piwnica-Worms; Joshua B Rubin
Journal:  Oncotarget       Date:  2014-10-30

9.  A restricted cell population propagates glioblastoma growth after chemotherapy.

Authors:  Jian Chen; Yanjiao Li; Tzong-Shiue Yu; Renée M McKay; Dennis K Burns; Steven G Kernie; Luis F Parada
Journal:  Nature       Date:  2012-08-23       Impact factor: 49.962

Review 10.  Aurora at the pole and equator: overlapping functions of Aurora kinases in the mitotic spindle.

Authors:  Helfrid Hochegger; Nadia Hégarat; Jose B Pereira-Leal
Journal:  Open Biol       Date:  2013-03-20       Impact factor: 6.411

View more
  2 in total

1.  Expression and prognostic role of E2F transcription factors in high-grade glioma.

Authors:  Hai Yu; Zhijin Li; Maode Wang
Journal:  CNS Neurosci Ther       Date:  2020-02-16       Impact factor: 5.243

Review 2.  The functional diversity of Aurora kinases: a comprehensive review.

Authors:  Estelle Willems; Matthias Dedobbeleer; Marina Digregorio; Arnaud Lombard; Paul Noel Lumapat; Bernard Rogister
Journal:  Cell Div       Date:  2018-09-19       Impact factor: 5.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.